The developing landscape of diabetes treatment is witnessing a exciting shift, driven by innovative incretin-based therapies. At this time, semaglutide has secured considerable traction, but emerging medications like tirzepatide, retatrutide, and cagrilintide are set to influence the outlook. Tirzepatide, a dual GIP and GLP-1 site agonist, delivers